中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
14期
2097-2098,2099
,共3页
肝炎,乙型%乙型肝炎e抗原%恩替卡韦%六味五灵片
肝炎,乙型%乙型肝炎e抗原%恩替卡韋%六味五靈片
간염,을형%을형간염e항원%은체잡위%륙미오령편
Hepatitis B%Hepatitis Be antigen%Entecavir%Liuwei wuling pian
目的：探讨恩替韦卡（ ETV）联合六味五灵片治疗乙型肝炎病毒e抗原阳性慢性乙型肝炎的疗效和安全性。方法将124例乙型肝炎病毒e抗原阳性慢性乙型肝炎患者采用随机数字表法分为两组，分别采用ETV联合六味五灵片治疗和单纯ETV治疗，比较两组肝功能及病毒复制指标。结果观察组有效率91．94％，对照组有效率82．26％，两组差异有统计学意义（Ridit＝32．251，P＜0．05）；治疗24周、48周，观察组HBV DNA低于对照组，差异有统计学意义（t＝2．365、4．595，均P＜0．05）；治疗后，观察组ALT、AST下降程度显著大于对照组（t＝78．512、62．145，均P＜0．05）；治疗后两组ALT复常率、总有效率和反跳率差异均有统计学意义（χ2＝25．621、46．241、11．512，均P＜0．05），HBV DNA和HBeAg阳性低于检测下限例数差异具有统计学意义（χ2＝17．265、21．264，均P＜0．05）。结论恩替韦卡联合六味五灵片治疗乙型肝炎病毒e抗原阳性慢性乙型肝炎能够减轻肝脏纤维化，并具有明显解毒和抗病毒作用。
目的：探討恩替韋卡（ ETV）聯閤六味五靈片治療乙型肝炎病毒e抗原暘性慢性乙型肝炎的療效和安全性。方法將124例乙型肝炎病毒e抗原暘性慢性乙型肝炎患者採用隨機數字錶法分為兩組，分彆採用ETV聯閤六味五靈片治療和單純ETV治療，比較兩組肝功能及病毒複製指標。結果觀察組有效率91．94％，對照組有效率82．26％，兩組差異有統計學意義（Ridit＝32．251，P＜0．05）；治療24週、48週，觀察組HBV DNA低于對照組，差異有統計學意義（t＝2．365、4．595，均P＜0．05）；治療後，觀察組ALT、AST下降程度顯著大于對照組（t＝78．512、62．145，均P＜0．05）；治療後兩組ALT複常率、總有效率和反跳率差異均有統計學意義（χ2＝25．621、46．241、11．512，均P＜0．05），HBV DNA和HBeAg暘性低于檢測下限例數差異具有統計學意義（χ2＝17．265、21．264，均P＜0．05）。結論恩替韋卡聯閤六味五靈片治療乙型肝炎病毒e抗原暘性慢性乙型肝炎能夠減輕肝髒纖維化，併具有明顯解毒和抗病毒作用。
목적：탐토은체위잡（ ETV）연합륙미오령편치료을형간염병독e항원양성만성을형간염적료효화안전성。방법장124례을형간염병독e항원양성만성을형간염환자채용수궤수자표법분위량조，분별채용ETV연합륙미오령편치료화단순ETV치료，비교량조간공능급병독복제지표。결과관찰조유효솔91．94％，대조조유효솔82．26％，량조차이유통계학의의（Ridit＝32．251，P＜0．05）；치료24주、48주，관찰조HBV DNA저우대조조，차이유통계학의의（t＝2．365、4．595，균P＜0．05）；치료후，관찰조ALT、AST하강정도현저대우대조조（t＝78．512、62．145，균P＜0．05）；치료후량조ALT복상솔、총유효솔화반도솔차이균유통계학의의（χ2＝25．621、46．241、11．512，균P＜0．05），HBV DNA화HBeAg양성저우검측하한례수차이구유통계학의의（χ2＝17．265、21．264，균P＜0．05）。결론은체위잡연합륙미오령편치료을형간염병독e항원양성만성을형간염능구감경간장섬유화，병구유명현해독화항병독작용。
Objective To explore the curative effect and safety of of Entecavir ( ETV) combined Liuweiwul-ing Pian in the treatment of chronic hepatitis B patients with HBeAg +.Methods 124 patients according to the ran-dom number table were divided into the two groups ,which respectively used ETV combined Liuweiwuling Pian treat-ment and ETV.The liver function and index of viral replication of the two groups were compared .Results The effec-tiveness of the observation group was 91.94%,which of the control group was 82.26%,the difference between the two groups had statistical significance(Ridit=32.251,P=0.000);Since 24 week treatment,HBV DNA of the observa-tion group was lower than the control group,the difference was statistically significant (t =2.365,4.595,all P<0.05);After treatment,ALT,AST of the observation group decreasing degree was higher than the control group ,the difference was statistically significant (t=78.512,62.145,all P<0.05);after treatment,the ALT rate,effective rate and bounce rate in the two groups was statistically significant differences (χ2 =25.621,46.241,11.512, all P<0.05);After treatment,the HBV DNA and HBeAg positive in two groups was below cut-off test cases,differences was statistically significant(χ2 =17.265,21.264,all P<0.05).Conclusion Entecavir combined Liuweiwuling Pian in the treatment of chronic hepatitis B patients with HBeAg +can reduce liver fibrosis , and has obvious detoxification and anti-viral.
